Loading
J&
Johnson & Johnson Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Dec 2025.
Johnson & Johnson: what insiders have been doing
Every trade that managers of Johnson & Johnson disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in New Brunswick, United States. It was founded in 1886. From 18 October 2025 to 18 October 2026, the disclosure feed for Johnson & Johnson logged 43 filings by 18 insiders.
Both sides are active: 1 purchase worth €223k and 12 sales worth €68.6M, from 1 insider and 5 insiders respectively. Taken together, the sales exceed the purchases by €68.4M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €23.2M, the sale published on 14 August 2026 by Duato Joaquin is the largest of the period (0.0041% of market cap). On the buying side, the filings list 1 senior executive among the declarants.
With 43 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 2 purchases and 28 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 28 December 2025 lists revenue at 94.19 bn USD and net income at 26.80 bn USD; the dividend was 5.14 USD per share.
The clock since the last published purchase (1 December 2025) now reads 321 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
241
Thresholds
n/a
Buy Volume
€362,938
2 ops. · all time
Sell Volume
€79M
28 ops. · all time
Who traded when
BuySaleJoaquin Duato5 sales
Timothy Schmid3 sales
Elizabeth Forminard2 sales
Jennifer L. Taubert1 sale
Morikis John G1 buy
Reed John C1 sale
+2 other insiders
Since the insiders bought
- +23.6%Entry US$205.42 · Close 14 Oct 2026 US$253.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Johnson & Johnson Buy (bullish), based on 22 analysts. Average price target: US$277.91.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 5,062 of 24,148 companies
66.3
score / 100
Value50
Quality83
FCF yld3.1%
Earn yld4.4%
EV/EBITDA16.2x
ROE26%
Gross mgn68%
Net mgn28%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$271.95
Analyst consensus
22 analystsBuy
US$190.00Target US$277.91(+2%)US$320.00
Income statement
RevenueUS$94.2B
Gross profitUS$63.9B68% margin
EBITDAUS$41.1B44% margin
Net incomeUS$26.8B21.5% margin
Valuation
PER (trailing)31.4x
PER (forward)22.4x
P/Book7.7x
Beta0.24
Balance sheet & cash
Market capUS$655.4B
Total debtUS$47.9B
Free Cash FlowUS$19.3B
Debt / Equity58%
Profitability & ownership
ROE25.7%
ROA8.6%
% insiders0.1%
% institutions76.7%
Last declaration on 4 September 2026
Declarations241 total
11,070 shares@ US$131.940.0002% mcap9.1% of flowCommon StockSEC:0000200406-26-000179:0
11,070 shares@ US$274.740.0005% mcap19.0% of flowCommon StockSEC:0000200406-26-000179:1
22,527 shares@ US$151.410.0005% mcap21.3% of flowCommon StockSEC:0000200406-26-000179:2
22,527 shares@ US$274.740.0009% mcap38.7% of flowCommon StockSEC:0000200406-26-000179:3
15,000 shares@ US$115.670.0003% mcap6.2% of flowCommon StockSEC:0000200406-26-000175:0
15,000 shares@ US$263.360.0006% mcap14.0% of flowCommon StockSEC:0000200406-26-000175:1
15,000 shares@ US$263.36120.0006% mcap14.0% of flowCommonSEC144:0001959173-26-006082
123,291 shares@ US$115.670.0022% mcap9.0% of flowCommon StockSEC:0000200406-26-000173:0
20,976 shares@ US$262.000.0008% mcap3.5% of flowCommon StockSEC:0000200406-26-000173:1
102,315 shares@ US$261.000.0041% mcap16.8% of flowCommon StockSEC:0000200406-26-000173:2
123,291 shares@ US$261.17010.0049% mcap20.3% of flowCommonSEC144:0001959173-26-005985
41,957 shares@ US$258.0560.0016% mcap6.8% of flowCommon StockSEC:0000200406-26-000171:0
6,523 shares@ US$258.7390.0003% mcap1.1% of flowCommon StockSEC:0000200406-26-000171:1
9,344 shares@ US$131.940.0002% mcap10.4% of flowCommon StockSEC:0000200406-26-000169:0
9,344 shares@ US$257.7550.0004% mcap20.3% of flowCommon StockSEC:0000200406-26-000169:1
6,574 shares@ US$255.9320.0003% mcap14.2% of flowCommon StockSEC:0000200406-26-000169:2
15,918 shares@ US$257.0020.0006% mcap34.5% of flowCommonSEC144:0001959173-26-005706
48,480 shares@ US$254.930.0019% mcap100.0% of flowCommon StockSEC144:0001968582-26-000782
11,129 shares@ US$129.510.0002% mcap8.5% of flowCommon StockSEC:0000200406-26-000148:0
11,925 shares@ US$131.940.0002% mcap9.3% of flowCommon StockSEC:0000200406-26-000148:1
23,054 shares@ US$251.2660.0009% mcap34.3% of flowCommon StockSEC:0000200406-26-000148:2
23,054 shares@ US$251.26610.0009% mcap34.3% of flowCommonSEC144:0001959173-26-005284
10,000 shares@ US$240.15390.0004% mcap12.0% of flowCommonSEC144:0001959173-26-004553
4,075 shares@ US$115.679.3% of flowCommon StockSEC:0000200406-26-000048:0
1,322 shares@ US$245.662.0% of flowCommon StockSEC:0000200406-26-000046:0
25 of 241 declarations
About Johnson & Johnson
Johnson & Johnson is a leading U.S. healthcare company listed on the NYSE under the ticker JNJ and headquartered in New Brunswick, New Jersey, United States. Founded in 1887, the company has built one of the most enduring franchises in global healthcare, with operations in virtually all countries and a business model anchored in scale, innovation, and diversification. For French, Belgian, and Swiss investors, JNJ is often viewed as a high-quality defensive large cap, combining pharmaceutical innovation with medical technology exposure and a long record of value creation and dividend growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf))
Johnson & Johnson is now organized into two core operating segments: Innovative Medicine and MedTech. Innovative Medicine covers research, development, manufacturing, and commercialization across major therapeutic areas including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. MedTech brings together a broad portfolio of solutions used in orthopaedics, surgery, cardiovascular care, and vision. This simpler structure gives investors clearer visibility into the group’s strategic priorities and underscores its focus on higher-value healthcare categories. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf))
Read moreShow less
From a competitive standpoint, JNJ benefits from several structural advantages: a powerful global brand, deep R&D capabilities, a broad clinical and commercial footprint, and a diversified product portfolio spanning both drugs and medical devices. The company competes in highly regulated, innovation-driven markets where intellectual property, clinical execution, and regulatory approvals are critical. Its products and services are sold to hospitals, physicians, distributors, retailers, and healthcare professionals across the United States and international markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf))
Key franchises include therapies in immunology and oncology, as well as advanced medical devices and surgical technologies. The company continues to emphasize next-generation platforms in oncology, autoimmune disease, and surgical innovation, supporting medium-term growth potential while balancing the maturity of some legacy categories. ([jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results))
Recent highlights include the publication of full-year 2025 results, a 2025 quarterly dividend increase, multiple regulatory approvals and product launches, and an October 2025 announcement of intent to separate the Orthopaedics business to sharpen strategic and operational focus. Overall, Johnson & Johnson remains a transformation story within large-cap healthcare, with a resilient balance between cash generation, innovation, and portfolio reshaping. ([jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
